Neurizon Therapeutics (ASX:NUZ) submitted a formal response to the US Food and Drug Administration (FDA) regarding the clinical hold on its investigational new drug application for NUZ-001, its lead therapy for amyotrophic lateral sclerosis, according to a Friday filing with the Australian bourse.
The response includes 28-day pharmacokinetic data from studies in rats and dogs to address the FDA's request for more comprehensive animal exposure data to support the safety margins of NUZ-001 and its primary sulfone metabolite, the filing said.
The review is now underway, and the company expects to receive formal feedback within 30 calendar days, per the filing.
Shares rose 19% in morning trade on Friday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。